Related references
Note: Only part of the references are listed.Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Filip Baert et al.
GUT (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease
Eran Zittan et al.
INFLAMMATORY BOWEL DISEASES (2016)
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2016)
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease
Giorgia Bodini et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test
Shiho Takashima et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
X. Roblin et al.
JOURNAL OF CROHNS & COLITIS (2015)
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Y. Mazor et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Practical application of acid dissociation in monitoring patients treated with adalimumab
Francisca Llinares-Tello et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
Yi-Lin Chiu et al.
INFLAMMATORY BOWEL DISEASES (2013)
Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab
Francisca Llinares-Tello et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2012)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Concepts and Lessons for Drug Development
Diane R. Mould et al.
BIODRUGS (2010)
Fecal Calprotectin Variability in Crohn's Disease
Bjorn Moum et al.
INFLAMMATORY BOWEL DISEASES (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
A review of activity indices and efficacy Endpoints for clinical trials of medical therapy in adults with Crohn's disease
WJ Sandborn et al.
GASTROENTEROLOGY (2002)
Share Paper
